Step-down arm Acrotech launches ADQUEY (difamilast 1%) ointment in the U.S., sets up dermatology unit
Acrotech Biopharma, a step-down subsidiary, has launched ADQUEY (difamilast 1%) ointment in the U.S. for mild-to-moderate atopic dermatitis in adults and children aged 2+.
- Product Name
- ADQUEY (difamilast 1%) ointment
- Indication
- mild-to-moderate atopic dermatitis in adults and children aged 2+
- Target Market Size
- US$ 1.3 billion (12 months ending July 2026, IQVIA MAT)
- Business Unit
- Dedicated dermatology business unit established
- Subsidiary
- Acrotech Biopharma, a step-down subsidiary
What was announced
Acrotech Biopharma Inc., a step-down subsidiary of Aurobindo Pharma Ltd., has launched ADQUEY (difamilast 1%) ointment in the United States.
- It is a non-steroidal topical PDE4 inhibitor.
- Indicated for mild-to-moderate atopic dermatitis (a common form of eczema).
- Approved for adults and pediatric patients 2 years of age and older.
- Discovered and developed by Otsuka Pharmaceutical Co., Ltd. and licensed to Acrotech for U.S. commercialization.
New business unit
To support the launch and longer-term plans, Acrotech has established a dedicated dermatology business unit with commercial capabilities across marketing, sales and field-based engagement. This marks Acrotech's entry into the U.S. dermatology market, a new therapeutic area for it.
Market context
The company states the product will compete in a market estimated at around US$ 1.3 billion for the twelve months ending July 2026, according to IQVIA MAT. This is the size of the addressable market, not a revenue forecast for the product.
How investors may read it
The launch adds a branded, licensed specialty product to the group's U.S. portfolio, diversifying beyond generics into dermatology. Building a dedicated field force involves upfront commercial spending, and uptake of a new branded topical depends on prescriber adoption, payer coverage and competition. The press release itself carries a forward-looking statements disclaimer, noting that actual outcomes may differ from expectations.
Also from Aurobindo Pharma
USFDA final approval received for Perampanel Tablets in 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg
3 Oct 2026
Subsidiary completes acquisition of A1 Biochem Group's contract research business
2 Oct 2026
Aurobindo arm A1 Biocheme USA Inc completes 100% acquisition of A1 Biocheme Labs LLC for USD 15.247 Mn
2 Oct 2026
More numbers
- Estimated U.S. market size for the product categoryUS$ 1.3 billion
- Minimum patient age indicated2 years of age and older
- ADQUEY ointment strength1%
- Countries where group commercializes productsover 150 countries
- Manufacturing and packaging facilities31 manufacturing and packaging facilities
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.